George Soros’s Acadia Pharmaceuticals ACAD Stock Holding History

George Soros’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-18,300	Closed	-$689K	–	195
2017 Q3	$689K	Buy	+18,300	New	+$595K	0.02%	147
2017 Q2	–	Sell	-8,900	Closed	-$306K	–	205
2017 Q1	$306K	Buy	+8,900	New	+$314K	0.01%	200
2016 Q4	–	Sell	-17,645	Closed	-$561K	–	208
2016 Q3	$561K	Buy	+17,645	New	+$598K	0.01%	161

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

George Soros's ACAD Position: Q4 2017 in Review

George Soros sold out of Acadia Pharmaceuticals (ACAD) in Q4 2017, closing a stake of 18,300 shares — an estimated $689K sold.

George Soros first reported a position in ACAD in Q3 2016 and held it in 3 quarters. The position peaked at $689K in Q3 2017. 210 funds tracked by Wall St. Rank hold ACAD as of Q4 2017.

George Soros reported no remaining Acadia Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
George Soros sold 18,300 Acadia Pharmaceuticals shares in Q4 2017, an estimated $689K.
George Soros first reported a position in Acadia Pharmaceuticals in Q3 2016 and held it in 3 quarters.
George Soros's Acadia Pharmaceuticals position peaked at $689K in Q3 2017.
210 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2017.

Based on Soros Fund Management's 13F filing for Q4 2017, filed 14 Feb 2018.